Plus Therapeutics (PSTV) appointed Michael Rosol as Chief Development Officer. Rosol will lead the company’s clinical, pre-clinical, and ...

(Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today ...

Dr. Rosol has 25 years of experience in clinical trial design, operations, and regulatory execution. Most recently, he served as Chief Medical Officer and Senior Vice President at Navidea ...

"It’s an exciting time to join Plus Therapeutics in this unique role," said Michael Rosol, Ph.D., Plus Therapeutics Chief Development Officer. "The Plus pipeline and recently reported clinical ...

The Company believes that these equity grants create a strong alignment of interests between Dr. Rosol and Company shareholders. The equity awards were granted outside of the Company's 2020 Incentive ...

Michael Rosol, the Company’s new Chief Development Officer. The Company agreed to grant these equity awards to Dr. Rosol to induce him to commence employment with the Company. The approved ...